Publications

  1. Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Sue LI, Jacobson SA, Belden CM, Dugger BN. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study. Neurology. 2014 Jul 29; 83(5):406-12. Epub 2014 Jun 27.
    View PubMed
  2. Jacobson SA, Morshed T, Dugger BN, Beach TG, Hentz JG, Adler CH, Shill HA, Sabbagh MN, Belden CM, Sue LI, Caviness JN, Hu C, the Arizona Parkinson's Disease Consortium. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat Disord. 2014 Jun 28.
    View PubMed
  3. Beach TG, Carew J, Serrano G, Adler CH, Shill HA, Sue LI, Sabbagh MN, Akiyama H, Cuenca N, Arizona Parkinson's Disease Consortium. Phosphorylated alpha-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. Neurosci Lett. 2014 Jun 13; 571:34-8. Epub 2014 Apr 28
    View PubMed
  4. Dugger BN, Adler CH, Shill HA, Caviness J, Jacobson S, Driver-Dunckley E, Beach TG, Arizona Parkinson's Disease Consortium. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord. 2014 May; 20(5):525-9. Epub 2014 Feb 22.
    View PubMed
  5. Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Jorge R, Biglan K, Caviness J, Olson B, Robinson RG, Kieburtz K, Paulsen JS. Results of the citalopram to enhance cognition in Huntington disease trial. Mov Disord. 2014 Mar; 29:401-5.
  6. Dugger BN, Hentz JG, Adler CH, Sabbagh MN, Shill HA, Jacobson S, Caviness JN, Belden C, Driver-Dunckley E, Davis KJ, Sue LI, Beach TG. Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropathol Exp Neurol. 2014 Mar; 73(3):244-52.
    View PubMed
  7. Caviness JN. Treatment of myoclonus. Neurotherapeutics. 2014 Jan; 11(1):188-200.
    View PubMed
  8. Caviness JN. Pathophysiology of Parkinson's disease behavior--a view from the network. Parkinsonism Relat Disord. 2014 Jan; 20 Suppl 1:S39-43.
    View PubMed
  9. Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Caviness J, Biglan K, Olson B, Paulsen JS. Does interval between screening and baseline matter in HD cognitive clinical trials? J Huntingtons Dis. 2014; 3(2):139-44.
    View PubMed
  10. Shneyder N, Adler CH, Hentz JG, Shill H, Caviness JN, Sabbagh MN, Beach TG, Driver-Dunckley E. Autonomic complaints in patients with restless legs syndrome. Sleep Med. 2013 Dec; 14(12):1413-6. Epub 2013 Sep 21.
    View PubMed
  11. Chen H, Burton EA, Ross GW, Huang X, Savica R, Abbott RD, Ascherio A, Caviness JN, Gao X, Gray KA, Hong JS, Kamel F, Jennings D, Kirshner A, Lawler C, Liu R, Miller GW, Nussbaum R, Peddada SD, Rick AC, Ritz B, Siderowf AD, Tanner CM, Troster AI, Zhang J. Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications. Environ Health Perspect. 2013 Nov-Dec; 121(11-12):1245-52. Epub 2013 Aug 07.
    View PubMed
  12. Mu L, Sobotka S, Chen J, Su H, Sanders I, Nyirenda T, Adler CH, Shill HA, Caviness JN, Samanta JE, Sue LI, Beach TG, Arizona Parkinson's Disease Consortium. Parkinson disease affects peripheral sensory nerves in the pharynx. J Neuropathol Exp Neurol. 2013 Jul; 72(7):614-23.
    View PubMed
  13. Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, Shill HA, Caviness JN, Samanta JE, Beach TG, Arizona Parkinson's Disease Consortium. Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol. 2013 Feb; 72(2):119-29.
    View PubMed
  14. Walker DG, Lue LF, Adler CH, Shill HA, Caviness JN, Sabbagh MN, Akiyama H, Serrano GE, Sue LI, Beach TG, Arizona Parkinson Disease Consortium. Changes in properties of serine 129 phosphorylated alpha-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol. 2013 Feb; 240:190-204. Epub 2012 Nov 28.
    View PubMed
  15. Henderson-Smith A, Chow D, Meechoovet B, Aziz M, Jacobson SA, Shill HA, Sabbagh MN, Caviness JN, Adler CH, Driver-Dunckley ED, Beach TG, Yin H, Dunckley T. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening. PLoS One. 2013; 8(10):e77711. Epub 2013 Oct 30.
    View PubMed
  16. Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, Sue LI, Caviness J, Sabbagh MN, Beach TG. Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol. 2012 Nov; 22(6):745-56. Epub 2012 Apr 12.
    View PubMed
  17. Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, Shill HA, Caviness JN, Samanta JE, Beach TG, Arizona Parkinson's Disease Consortium. Altered pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol. 2012 Jun; 71(6):520-30.
    View PubMed
  18. Dugger BN, Serrano GE, Sue LI, Walker DG, Adler CH, Shill HA, Sabbagh MN, Caviness JN, Hidalgo J, Saxon-Labelle M, Chiarolanza G, Mariner M, Henry-Watson J, Beach TG, the Arizona Parkinson's Disease Consortium. Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. J Parkinsons Dis. 2012 Jan 1; 2(1):57-65.
    View PubMed
  19. Caviness JN. Presymptomatic Parkinson's disease: the Arizona experience. Parkinsonism Relat Disord. 2012 Jan; 18 Suppl 1:S203-6.
    View PubMed
  20. Shill HA, Adler CH, Beach TG, Lue LF, Caviness JN, Sabbagh MN, Sue LI, Walker DG. Brain biochemistry in autopsied patients with essential tremor. Mov Disord. 2012 Jan; 27(1):113-7. Epub 2011 Oct 28.
    View PubMed
  21. Lyons MK, Behbahani M, Boucher OK, Caviness JN, Evidente VG. Orthostatic tremor responds to bilateral thalamic deep brain stimulation. Tremor Other Hyperkinet Mov (N Y). 2012; 2. Epub 2012 Feb 20.
    View PubMed
  22. *Damian A, Adler CH, Hentz JG, Shill HA, Caviness JN, Sabbagh MN, Evidente VGH, Beach TG, Driver-Dunckley E. Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. Parkinsonism Relat Disord. 2012; 18(10):1089-93.
  23. Caviness JN, Adler CH, Hentz JG, Shill HA, Evidente VG, Driver-Dunckley ED, Sabbagh MN, Sue L, Beach TG. Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders. Clin Neurophysiol. 2011 Dec; 122(12):2426-32. Epub 2011 May 26.
    View PubMed
  24. Adler CH, Crews D, Kahol K, Santello M, Noble B, Hentz JG, Caviness JN. Are the yips a task-specific dystonia or "golfer's cramp"? Mov Disord. 2011 Sep; 26(11):1993-6. Epub 2011 Jun 14.
    View PubMed
  25. Evidente VG, Premkumar AP, Adler CH, Caviness JN, Driver-Dunckley E, Lyons MK. Medication dose reductions after pallidal versus subthalamic stimulation in patients with Parkinson's disease. Acta Neurol Scand. 2011 Sep; 124(3):211-4. Epub 2010 Oct 25.
    View PubMed
  26. Klassen BT, Hentz JG, Shill HA, Driver-Dunckley E, Evidente VG, Sabbagh MN, Adler CH, Caviness JN. Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurology. 2011 Jul 12; 77(2):118-24. Epub 2011 Jun 01.
    View PubMed
  27. Adler CH, Hentz JG, Shill HA, Sabbagh MN, Driver-Dunckley E, Evidente VG, Jacobson SA, Beach TG, Boeve B, Caviness JN. Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome. Parkinsonism Relat Disord. 2011 Jul; 17(6):456-8. Epub 2011 Apr 08.
    View PubMed
  28. Caviness JN, Lue LF, Beach TG, Hentz JG, Adler CH, Sue L, Sadeghi R, Driver-Dunckley E, Evidente VG, Sabbagh MN, Shill HA, Walker DG. Parkinson's disease, cortical dysfunction, and alpha-synuclein. Mov Disord. 2011 Jul; 26(8):1436-42. Epub 2011 May 03.
    View PubMed
  29. Evidente VG, Adler CH, Sabbagh MN, Connor DJ, Hentz JG, Caviness JN, Sue LI, Beach TG. Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP? Parkinsonism Relat Disord. 2011 Jun; 17(5):365-71. Epub 2011 Mar 21.
    View PubMed
  30. Caviness JN, Lue L, Adler CH, Walker DG. Parkinson's disease dementia and potential therapeutic strategies. CNS Neurosci Ther. 2011 Feb; 17(1):32-44. Epub 2010 Dec 28.
    View PubMed
  31. Damian AM, Jacobson SA, Hentz JG, Belden CM, Shill HA, Sabbagh MN, Caviness JN, Adler CH. The Montreal Cognitive Assessment and the mini-mental state examination as screening instruments for cognitive impairment: item analyses and threshold scores. Dement Geriatr Cogn Disord. 2011; 31(2):126-31. Epub 2011 Jan 29.
    View PubMed
  32. Caviness JN, Truong DD. Myoclonus. Handb Clin Neurol. 2011; 100:399-420.
    View PubMed
  33. Lansford KL, Liss JM, Caviness JN, Utianski RL. A cognitive-perceptual approach to conceptualizing speech intelligibility deficits and remediation practice in Hypokinetic dysarthria. Parkinson's Disease. 2011; 150962.
  34. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG, Arizona Parkinson's Disease Consortium. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010 Jun; 119(6):689-702. Epub 2010 Mar 21.
    View PubMed
  35. Choi SA, Evidente VG, Caviness JN. Comparing Cerebral White Matter Lesion Burdens between Parkinson's Disease with and without Dementia. J Mov Disord. 2010 May; 3(1):6-10. Epub 2010 Apr 30.
    View PubMed
  36. Adler CH, Connor DJ, Hentz JG, Sabbagh MN, Caviness JN, Shill HA, Noble B, Beach TG. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord. 2010 Apr 15; 25(5):642-6.
    View PubMed
  37. McKinnon J, Evidente V, Driver-Dunckley E, Premkumar A, Hentz J, Shill H, Sabbagh M, Caviness J, Connor D, Adler C. Olfaction in the elderly: a cross-sectional analysis comparing Parkinson's disease with controls and other disorders. Int J Neurosci. 2010 Jan; 120(1):36-9.
    View PubMed
  38. Liss JM, White L, Mattys SL, Lansford K, Lotto AJ, Spitzer SM, Caviness JN. Quantifying speech rhythm abnormalities in the dysarthrias. J Speech Lang Hear Res. 2009 Oct; 52(5):1334-52. Epub 2009 Aug 28.
    View PubMed
  39. Driver-Dunckley E, Connor D, Hentz J, Sabbagh M, Silverberg N, Hernandez J, Vedders L, Evidente VG, Shill H, Caviness J, Adler C. No evidence for cognitive dysfunction or depression in patients with mild restless legs syndrome. Mov Disord. 2009 Sep 15; 24(12):1840-2.
    View PubMed
  40. Caviness JN. Pathophysiology and treatment of myoclonus. Neurol Clin. 2009 Aug; 27(3):757-77, vii.
    View PubMed
  41. Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, Caviness JN, Shill HA, Sue LI, Ziabreva I, Perry E, Ballard CG, Aarsland D, Walker DG, Beach TG. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):295-7.
    View PubMed
  42. Sabbagh MN, Sandhu SS, Farlow MR, Vedders L, Shill HA, Caviness JN, Connor DJ, Sue L, Adler CH, Beach TG. Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):229-33.
    View PubMed
  43. Almaraz AC, Driver-Dunckley ED, Woodruff BK, Wellik KE, Caselli RJ, Demaerschalk BM, Adler CH, Caviness JN, Wingerchuk DM. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. Neurologist. 2009 Jul; 15(4):234-7.
    View PubMed
  44. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL III, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG. Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (Berl). 2009 Jun; 117(6):613-34.
    View PubMed
  45. Alvarez MV, Driver-Dunckley EE, Caviness JN, Adler CH, Evidente VG. Case series of painful legs and moving toes: clinical and electrophysiologic observations. Mov Disord. 2008 Oct 30; 23(14):2062-6.
    View PubMed
  46. Alvarez M, Caviness JN. Primary progressive myoclonus of aging. Mov Disord. 2008 Sep 15; 23(12):1658-64.
    View PubMed
  47. Stamper C, Siegel A, Liang WS, Pearson JV, Stephan DA, Shill H, Connor D, Caviness JN, Sabbagh M, Beach TG, Adler CH, Dunckley T. Neuronal gene expression correlates of Parkinson's disease with dementia. Mov Disord. 2008 Aug 15; 23(11):1588-95.
    View PubMed
  48. Shill HA, Adler CH, Sabbagh MN, Connor DJ, Caviness JN, Hentz JG, Beach TG. Pathologic findings in prospectively ascertained essential tremor subjects. Neurology. 2008 Apr 15; 70(16 Pt 2):1452-5.
    View PubMed
  49. Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez JE, Lue LF, Caviness JN, Connor DJ, Sabbagh MN, Walker DG. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 2008 Apr; 115(4):445-51. Epub 2007 Nov 06.
    View PubMed
  50. Weismer G, Barlow S, Smith A, Caviness J. Special Panel Session: Driving Critical Initiatives in Motor Speech. J Med Speech Lang Pathol. 2008; 16(4):283.
    View PubMed
  51. McKinnon JH, Demaerschalk BM, Caviness JN, Wellik KE, Adler CH, Wingerchuk DM. Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders? Neurologist. 2007 Nov; 13(6):382-5.
    View PubMed
  52. Beach TG, Sue LI, Walker DG, Lue LF, Connor DJ, Caviness JN, Sabbagh MN, Adler CH. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol (Berl) 2007 Oct; 114(4):419-24. Epub 2007 Jul 17.
    View PubMed
  53. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, Krahn L, Adler CH. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):249-55.
    View PubMed
  54. Caviness JN, Hentz JG, Evidente VG, Driver-Dunckley E, Samanta J, Mahant P, Connor DJ, Sabbagh MN, Shill HA, Adler CH. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. Parkinsonism Relat Disord. 2007 Aug; 13(6):348-54. Epub 2007 Mar 08.
    View PubMed
  55. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH. Defining mild cognitive impairment in Parkinson's disease. Mov Disord. 2007 Jul 15; 22(9):1272-7.
    View PubMed
  56. Arvanitakis Z, Witte RJ, Dickson DW, Tsuboi Y, Uitti RJ, Slowinski J, Hutton ML, Lin SC, Boeve BF, Cheshire WP, Pooley RA, Liss JM, Caviness JN, Strongosky AJ, Wszolek ZK. Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism Relat Disord. 2007 May; 13(4):230-9. Epub 2006 Dec 29.
    View PubMed
  57. Sabbagh MN, Lahti T, Connor DJ, Caviness JN, Shill H, Vedders L, Mahant P, Samanta J, Burns RS, Evidente VG, Driver-Dunckley E, Reisberg B, Bircea S, Adler CH. Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease. Dement Geriatr Cogn Disord. 2007; 24(5):327-34. Epub 2007 Sep 13.
    View PubMed
  58. Caviness JN. Parkinsonism & related disorders. Myoclonus. Parkinsonism Relat Disord. 2007; 13 Suppl 3:S375-84.
    View PubMed
  59. Langbehn DR, Paulsen JS, Hedges P, McCusker E, Pearce S, Trent R, Abwender D, Como P, Gardiner I, Hickey C, Kayson E, Kieburtz K, Marshall F, Pearson N, Shoulson I, Zimmerman C, Louis E, Marder K, Moskowitz C, Polanco C, Taylor S, Zubin N, Brown C, Predictors of diagnosis in Huntington disease. Neurology. 2007; 68(20):1710-7.
    View PubMed
  60. Liss JM, Krein-Jones K, Wszolek ZK, Caviness JN. Speech characteristics of patients with pallido-ponto-nigral degeneration and their application to presymptomatic detection in at-risk relatives. Am J Speech Lang Pathol. 2006 Aug; 15(3):226-35.
    View PubMed
  61. Hoffman Snyder C, Mishark KJ, Caviness JN, Drazkowski JF, Caselli RJ. Nonvasculitic autoimmune inflammatory meningoencephalitis imitating Creutzfeldt-Jakob disease. Arch Neurol. 2006 May; 63(5):766-8.
    View PubMed
  62. Caviness JN, Liss JM, Adler C, Evidente V. Analysis of high-frequency electroencephalographic-electromyographic coherence elicited by speech and oral nonspeech tasks in Parkinson's disease. J Speech Lang Hear Res. 2006 Apr; 49(2):424-38.
    View PubMed
  63. Caviness JN, Shill HA, Sabbagh MN, Evidente VG, Hernandez JL, Adler CH. Corticomuscular coherence is increased in the small postural tremor of Parkinson's disease. Mov Disord. 2006 Apr; 21(4):492-9.
    View PubMed
  64. Tsuboi Y, Josephs KA, Boeve BF, Litvan I, Caselli RJ, Caviness JN, Uitti RJ, Bott AD, Dickson DW. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord. 2005 Aug; 20(8):982-8.
    View PubMed
  65. Sabbagh MN, Silverberg N, Bircea S, Majeed B, Samant S, Caviness JN, Reisberg B, Adler CH. Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease? Parkinsonism Relat Disord. 2005 Aug; 11(5):311-5.
    View PubMed
  66. Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol. 2004 Oct; 3(10):598-607.
    View PubMed
  67. Badhwar A, Berkovic SF, Dowling JP, Gonzales M, Narayanan S, Brodtmann A, Berzen L, Caviness J, Trenkwalder C, Winkelmann J, Rivest J, Lambert M, Hernandez-Cossio O, Carpenter S, Andermann F, Andermann E. Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain. 2004 Oct; 127(Part 10):2173-82.
    View PubMed
  68. Adler CH, Bansberg SF, Hentz JG, Ramig LO, Buder EH, Witt K, Edwards BW, Krein-Jones K, Caviness JN. Botulinum toxin type A for treating voice tremor. Arch Neurol. 2004 Sep; 61(9):1416-20.
    View PubMed
  69. Adler CH, Hauser RA, Sethi K, Caviness JN, Marlor L, Anderson WM, Hentz JG. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology. 2004 Apr 27; 62(8):1405-7.
    View PubMed
  70. Caviness JN, Adler CH, Sabbagh MN, Connor DJ, Hernandez JL, Lagerlund TD. Abnormal corticomuscular coherence is associated with the small amplitude cortical myoclonus in Parkinson's disease. Mov Disord. 2003 Oct; 18(10):1157-62.
    View PubMed
  71. Evidente VG, Caviness JN, Adler CH. Case studies in movement disorders. Semin Neurol. 2003 Sep; 23(3):277-84.
    View PubMed
  72. Caviness JN. Myoclonus and neurodegenerative disease - what's in a name? Parkinsonism & Related Disorders. 2003 Mar; 9(4):185-92.
    View PubMed
  73. Caviness JN, Evidente VG. Cortical myoclonus during lithium exposure. Arch Neurol. 2003 Mar; 60(3):401-4.
    View PubMed
  74. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord. 2003 Mar; 18(3):287-93.
    View PubMed
  75. Caviness JN, Tsuboi Y, Wszolek ZK. Clinical-electrophysiological correlation of tremor and myoclonus in a kindred with the N279K tau mutation. Parkinsonism & Related Disorders. 2003 Jan; 9(3):151-7.
    View PubMed
  76. Caviness JN. Chapter 32 The clinical neurophysiology of myoclonus. Handbook of Clinical Neurophysiology. 2003; 1(C):521-48.
  77. Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN. Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism & Related Disorders. 2002 Dec; 9(2):103-10.
    View PubMed
  78. Liss JM, Spitzer SM, Caviness JN, Adler C. The effects of familiarization on intelligibility and lexical segmentation in hypokinetic and ataxic dysarthria. J Acoust Soc Am. 2002 Dec; 112(6):3022-30.
    View PubMed
  79. Joyce JN, Ryoo HL, Beach TB, Caviness JN, Stacy M, Gurevich EV, Reiser M, Adler CH. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D-3 and not D-2 receptors. Brain Res. 2002 Nov 15; 955(1-2):138-52.
    View PubMed
  80. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Small-amplitude cortical myoclonus in Parkinson's disease: Physiology and clinical observations. Mov Disord. 2002 Jul; 17(4):657-62.
    View PubMed
  81. Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ, Blasucci L, Caviness JN, Leurgans S, Chase WM, Yones LC, Tan E, Carvey P, Goetz CG. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
    View PubMed
  82. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Hentz JG, Manfred MS, Muenter D. Motor unit number estimates in idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2002 Jan; 8(3):161-4.
    View PubMed
  83. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Myoclonus in Lewy body disorders. Adv Neurol. 2002; 89:23-30.
    View PubMed
  84. Caviness JN. Epidemiology of myoclonus. Adv Neurol. 2002; 89:19-22.
    View PubMed
  85. Ahlskog JE, Nishino H, Evidente VG, Tulloch JW, Forbes GS, Caviness JN, Gwinn-Hardy KA. Persistent chorea triggered by hyperglycemic crisis in diabetics. Mov Disord. 2001 Sep; 16(5):890-8.
    View PubMed
  86. Evidente VG, Caviness JN, Adler CH, Gwinn-Hardy KA, Pratley RE. Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss. Mov Disord. 2001 Sep; 16(5):924-7.
    View PubMed
  87. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001 Jun 12; 56(11):1523-8.
    View PubMed
  88. Caviness JN. Primary care guide to myoclonus and chorea. Characteristics, causes and clinical options. Postgrad Med. 2000 Oct; 108(5):163-6, 169-72.
    View PubMed
  89. Cooper C, Evidente VG, Hentz JG, Adler CH, Caviness JN, Gwinn-Hardy K. The effect of temperature on hand function in patients with tremor. J Hand Ther. 2000 Oct-Dec; 13(4):276-88.
    View PubMed
  90. Liss JM, Spitzer SM, Caviness JN, Adler C, Edwards BW. Lexical boundary error analysis in hypokinetic and ataxic dysarthria. J Acoust Soc Am. 2000 Jun; 107(6):3415-24.
    View PubMed
  91. Evidente VG, Gwinn-Hardy KA, Caviness JN, Gilman S. Hereditary ataxias. Mayo Clin Proc. 2000 May; 75(5):475-90.
    View PubMed
  92. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Reiners CA, Hentz JG, Muenter MD. Motor unit changes in sporadic idiopathic Parkinson's disease. Mov Disord. 2000 Mar; 15(2):238-43.
    View PubMed
  93. Evidente VG, Adler CH, Caviness JN, Hentz JG, Gwinn-Hardy K. Amantadine is beneficial in restless legs syndrome. Mov Disord. 2000 Mar; 15(2):324-7.
    View PubMed
  94. Gwinn-Hardy KA, Crook R, Lincoln S, Adler CH, Caviness JN, Hardy J, Farrer M. A kindred with Parkinson's disease not showing genetic linkage to established loci. Neurology. 2000 Jan 25; 54(2):504-7.
    View PubMed
  95. Pratley RE, Salbe AD, Ravussin E, Caviness JN. Higher sedentary energy expenditure in patients with Huntington's disease. Ann Neurol. 2000 Jan; 47(1):64-70.
    View PubMed
  96. Caviness JN, Gwinn-Hardy K, Adler CH, Muenter MD. Electrophysical observations in hereditary Parkinsonism-dementia with Lewy body pathology. Mov Disord. 2000 Jan; 15(1):140-145.
    View PubMed
  97. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I, Caviness JN, The Huntington Study Group. Rate of functional decline in Huntington’s disease. Neurology. 2000; 54:452-8.
    View PubMed
  98. Spitzer SM, Liss JM, Caviness JN, Adler CH. An exploration of familiarization effects in the perception of hypokinetic and ataxic dysarthic speech. J of Med Speech-Language Path. 2000; 8:285-93.
  99. Caviness JN, Alving LI, Maraganore DM, Black RA, McDonnell SK, Rocca WA. The incidence and prevalence of myoclonus in Olmsted County, Minnesota. Mayo Clin Proc. 1999 Jun; 74(6):565-9.
    View PubMed
  100. Caselli RJ, Stelmach GE, Caviness JN, Timmann D, Royer T, Boeve BF, Parisi JE. A kinematic study of progressive apraxia with and without dementia. Mov Disord. 1999 Mar; 14(2):276-87.
    View PubMed
  101. Evidente VG, Caviness JN, Jamieson B, Weaver A, Joshi N. Intersubject variability and intrasubject reproducibility of the bereitschaftspotential. Mov Disord. 1999 Mar; 14(2):313-9.
    View PubMed
  102. Evidente VG, Gwinn-Hardy K, Caviness JN, Alder CH. Risperidone is effective in severe hemichorea/hemiballismus. Mov Disord. 1999 Mar; 14(2):377-9.
    View PubMed
  103. Evidente VG, Caviness JN. Focal cortical transient preceding myoclonus during lithium and tricyclic antidepressant therapy. Neurology. 1999 Jan 1; 52(1):211-3.
    View PubMed
  104. Evidente VG, Adler CH, Caviness JN, Gwinn-Hardy K. A pilot study on the motor effects of rimantadine in Parkinson's disease. Clin Neuropharmacol. 1999 Jan-Feb; 22(1):30-2.
    View PubMed
  105. Liss JM, Spitzer S, Caviness JN, Adler C, Edwards B. Syllabic strength and lexical boundary decisions in the perception of hypokinetic dysarthric speech. J Acoust Soc Am. 1998 Oct; 104(4):2457-66.
    View PubMed
  106. Evidente VG, Adler CH, Caviness JN, Gwinn KA. Effective treatment of orthostatic tremor with gabapentin. Mov Disord. 1998 Sep; 13(5):829-31.
    View PubMed
  107. Evidente VG, Gwinn KA, Caviness JN, Hirschorn K, Deen HG. Surgically responsive focal tremor associated with a frontal convexity meningioma. Eur Neurol. 1998 Aug; 40(2):107-8.
    View PubMed
  108. Caviness JN, Adler CH, Newman S, Caselli RJ, Muenter MD. Cortical myoclonus in levodopa-responsive parkinsonism. Mov Disord. 1998 May; 13(3):540-4.
    View PubMed
  109. Evidente VG, Gwinn KA, Caviness JN, Muenter M, Mulder DW. Early cinematographic cases of postencephalitic parkinsonism and other movement disorders. Mov Disord. 1998 Jan; 13(1):167-9.
    View PubMed
  110. Caviness JN, Kurth M. Cortical Myoclonus in Huntington's disease associated with an enlarged somatosensory evoked potential. Mov Disord. 1997 Nov; 12(6):1046-51.
    View PubMed
  111. Uitti RJ, Wharen RE Jr, Turk MF, Lucas JA, Finton MJ, Graff-Radford NR, Boylan KB, Goerss SJ, Kall BA, Adler CH, Caviness JN, Atkinson EJ. Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patients. Neurology. 1997 Oct; 49(4):1072-7.
    View PubMed
  112. Adler CH, Caviness JN. Dystonia secondary to electrical injury: surface electromyographic evaluation and implications for the organicity of the condition. J Neurol Sci. 1997 May 29; 148(2):187-92.
    View PubMed
  113. Gwinn KA, Caviness JN. Electrophysiological observations in idiopathic opsoclonus-myoclonus syndrome. Mov Disord. 1997 May; 12(3):438-42.
    View PubMed
  114. Kurth MC, Adler CH, Sthilaire M, Singer C, Waters C, Lewitt P, Chernik DA, Dorflinger EE, Yoo K, Lieberman AN, Brewer M, Sainthilaire M, Pery LM, Thomas C, Turpin L, Obrien CF, Seeberger LC, Duncan KL, Caviness JN, Douglas M, Wheeler K, Riley D, Rainey P, Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations - a multicenter, double blind, randomized, placebo-controlled trial. Neurology. 1997 Jan; 48(1):81-87.
    View PubMed
  115. Gwinn KA, Caviness JN. Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord. 1997 Jan; 12(1):119-21.
    View PubMed
  116. Lieberman A, Caviness JN, The Pramipexole Study Group. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controled, parallel-group study. Neurology. 1997; 49(162-8).
  117. Weber JG, Cunnien AJ, Hinni ML, Caviness JN. Psychogenic coma after use of general anesthesia for ethmoidectomy. Mayo Clin Proc. 1996 Aug; 71(8):797-800.
    View PubMed
  118. Caviness JN. Myoclonus. Mayo Clin Proc. 1996 Jul; 71(7):679-88.
    View PubMed
  119. Caviness JN, Forsyth PA, Layton DD, McPhee TJ. The movement disorder of adult opsoclonus. Mov Disord. 1995 Jan; 10(1):22-7.
    View PubMed
  120. Matsumoto JY, Caviness JN, McEvoy KM. The acoustic startle reflex in stiff-man syndrome. Neurology. 1994 Oct; 44(10):1952-5.
    View PubMed
  121. Muenter MD, Daube JR, Caviness JN, Miller PM. Treatment of essential tremor with methazolamide. Mayo Clin Proc. 1991 Oct; 66(10):991-7.
    View PubMed
  122. Caviness JN, Muenter MD. An unusual cause of recurrent chorea. Mov Disord. 1991; 6(4):355-7.
    View PubMed
  123. Caviness JN, Wightman RM. Use of rapid superfusion to differentiate the release of dopamine from striatal tissue induced by sympathomimetic amines from release induced by potassium. Journal of Pharmacology & Experimental Therapeutics. 1982 Oct; 223(1):90-6.
    View PubMed
  124. Wightman RM, Bright CE, Caviness JN. Direct measurement of the effect of potassium, calcium, veratridine, and amphetamine on the rate of release of dopamine from superfused brain tissue. Life Sci. 1981 Mar 16; 28(11):1279-86.
    View PubMed